NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Excerpt
The evidence reviewed for this guideline has highlighted the lack of useful national data on 19 pancreatic cancer in the UK. In many cancers, national datasets have contributed 20 significantly to improving outcomes of patient management. For pancreatic cancer, there has 21 been no comprehensive national database and therefore comparing outcomes between 22 pancreatic centres and pancreatic specialists has not been possible. This lack of continuous 23 audit may result in inappropriate variation in the standard of treatments between centres. The 24 Committee is of the unanimous opinion that a national database of pancreatic cancer 25 patients needs to be established to provide a continuous comparative audit of patient 26 management.
Contents
- 1. Introduction
- 2. Guideline summary
- 3. Development of this guideline
- 4. Guideline development methodology
- 5. Diagnosis
- 6. Referral to specialist multidisciplinary teams
- 7. Staging
- 8. Support needs
- 9. Interventions to relieve biliary and duodenal obstruction
- 10. Management of resectable and borderline resectable pancreatic cancer
- 11. Management of unresectable pancreatic cancer
- 12. Economic modelling: cost effectiveness of different types of stent for the management of biliary obstruction in people with unresectable pancreatic cancer
- 13. Network Meta-Analysis (Mixed Treatment Comparison) and Economic Model on treatment of unresectable locally advanced non-metastatic pancreatic cancer
- Appendix A. Scope
- Appendix B. Stakeholders
- Appendix C. Review protocols
- Appendix D. Combined Search Strategy
- Appendix E. Prisma Flow Charts
- Appendix F. Evidence tables
- Appendix G. Excluded studies
- Appendix H. Forest plots and Summary ROC curves
- Appendix I. GRADE Tables
- Appendix J. Risk of bias summaries
- Appendix K. Health economics evidence profiles
- Appendix L. Health economics evidence tables
Final
National Guideline Alliance, hosted by the Royal College of Obstetricians and Gynaecologists
Disclaimer
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.
NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn.
- NLM CatalogRelated NLM Catalog Entries
- Review The UK Haemophilia Doctors Organisation triennial audit of UK Comprehensive Care Haemophilia Centres.[Haemophilia. 2012]Review The UK Haemophilia Doctors Organisation triennial audit of UK Comprehensive Care Haemophilia Centres.Wilde JT. Haemophilia. 2012 Jul; 18(4):491-5. Epub 2012 May 8.
- Review Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.[Health Technol Assess. 2007]Review Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.Facey K, Bradbury I, Laking G, Payne E. Health Technol Assess. 2007 Oct; 11(44):iii-iv, xi-267.
- The future of Cochrane Neonatal.[Early Hum Dev. 2020]The future of Cochrane Neonatal.Soll RF, Ovelman C, McGuire W. Early Hum Dev. 2020 Nov; 150:105191. Epub 2020 Sep 12.
- Review Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups.[Health Technol Assess. 2004]Review Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups.Beswick AD, Rees K, Griebsch I, Taylor FC, Burke M, West RR, Victory J, Brown J, Taylor RS, Ebrahim S. Health Technol Assess. 2004 Oct; 8(41):iii-iv, ix-x, 1-152.
- The Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia.[Intern Med J. 2019]The Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia.Mileshkin L, Dunn C, Cross H, Duffy M, Shaw M, Antippa P, Mitchell P, Akhurst T, Conron M, Moore M, et al. Intern Med J. 2019 Aug; 49(8):1001-1006.
- Pancreatic cancer in adults: diagnosis and managementPancreatic cancer in adults: diagnosis and management
Your browsing activity is empty.
Activity recording is turned off.
See more...